Substitute for form 1449A/PT	
	$\sim$



## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

			_
Sheet	1	of	1

C	te if Known	
Application Number	10/510,020	
Filing Date	October 1, 2004	
First Named Inventor	Jukka SALLINEN	
Art Unit		
Examiner Name		
Attorney Docket Number	09602.0001	

	U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS						
Examiner	Cite	Document Number	Issue or		Name of Patentee or	Pages, Columns, Lines, Where	
Initials	No.¹	Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
		US-					
		US-					

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
/K.C./		Neal R. Swerdlow et al., "Assessing the Validity of an Animal Model of Deficient Sensorimotor Gating in Schizophrenic Patients," Arch Gen Psychiatry, Vol. 51, pp. 139-154, 1994	
300000000000000000000000000000000000000		David L. Braff et al., "Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies," Psychopharmacology, Vol. 156, pp. 234-258, 2001	
223000000000000000000000000000000000000		S. Ludewig et al., "Prepulse Inhibition Deficits in Patients with Panic Disorder," Depression and Anxiety, Vol. 15, pp. 55-60, 2002	
***************************************		Ewen MacDonald et al., "Gene targeting - homing in on $\alpha_2$ -adrenoceptor-subtype function," Trends in Pharmacological Sciences, Vol. 18, pp. 211-219, 1997	
ообоооооооооооо		M. Scheinin et al., "Evaluation of the $\alpha_{2C}$ -adrenoceptor as a neuropsychiatric drug target, Studies in transgenic mouse models," Life Sciences, Vol. 68, pp. 2277-2285, 2001	
***************************************		Mark A. Geyer et al., "Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review," Psychopharmacology, Vol. 156, pp. 117-154, 2001	
COCCOCOCOCOCOCOCOCOCOCOCOCOCOCOCOCOCOCOC		Jukka Sallinen et al., "Adrenergic $\alpha_{2C}$ -Receptors Modulate the Acoustic Startle Reflex, Prepulse Inhibition, and Aggression in Mice," The Journal of Neuroscience, Vol. 18, pp. 3035-3042, 1998	
V		Antti Haapalinna et al., "Evaluation of the effects of a specific $\alpha_2$ -adrenoceptor antagonist, atipamezole, on $\alpha_1$ - and $\alpha_2$ -adrenoceptor subtype binding, brain neurochemistry and behavior in comparison with yohimbine," Naunyn-Schmiedeberg's Arch. Pharmacol, Vol. 356, pp. 570-582, 1997	

				·
Examiner	// addaula in Oxyan/	Date	00/40/0000	
Signature	/Kathrien Cruz/	1 =	1 114/14/2000	
Signature	The control of the co	Considered	00/10/2000	
			<u> </u>	